Leinco Technologies and CellCarta Form Strategic Partnership to Advance Proteomics in Immuno-Oncology Drug Development
核心洞察
Leinco Technologies and CellCarta announced a strategic collaboration combining validated antibodies with Immuno-MRM assays to enhance proteomics solutions for drug development.
The partnership integrates Leinco's high-quality antibodies for tissue analysis with CellCarta's CPTAC-validated antibody library designed for multiplexed protein measurements.
The collaboration aims to accelerate biomarker discovery and therapeutic target evaluation by providing scalable solutions from exploratory research to clinical implementation.
Leinco TechnologiesSearch company, a leader in antibody and protein development, and CellCartaSearch company, a global provider of precision medicine laboratory services, announced a strategic collaboration on April 23, 2026, aimed at advancing proteomics solutions for immuno-oncologySearch disease and other targeted therapeutic modalities. The partnership combines complementary technologies to create comprehensive tools for biomarker discovery and clinical research.
Enhanced Proteomics Platform Integration
The collaboration integrates Leinco's extensive antibody portfolio with CellCartaSearch company's catalogue of CPTACSearch company antibodies developed for Immuno-MRM assays. Leinco contributes high-quality antibodies validated for critical tissue analysis applications including immunohistochemistry (IHC) and spatial biology platforms, while CellCarta provides antibodies validated to meet CPTAC consortium standards.
CellCartaSearch company's Immuno-MRM assays offer highly multiplexed and quantitative protein measurements, enabling precise quantification of specific targets in clinical samples. These assays provide valuable insights into protein expression and functionality, with an antibody library designed to support research from exploratory studies through clinical trials.
"The combination of our rigorously validated antibodies—especially those proven for complex spatial analysis and IHC—with CellCartaSearch company's robust Immuno-MRM resources creates a truly powerful and scalable solution for our customers," said Patrick Leinert Jr., President of Commercial Operations at Leinco TechnologiesSearch company. "This strategic pairing is designed to provide confidence in data quality that is absolutely essential for accelerating drug development and biomarker discovery in all therapeutic areas."
Scalable Solutions for Research and Clinical Applications
The partnership addresses diverse research needs by offering scalable solutions spanning pilot-scale research to large-volume clinical applications. Researchers can access smaller catalog sizes for exploratory studies, while clinical laboratories can utilize large-volume reagents for routine testing.
"By providing our immuno-MRM antibody library to Leinco, CellCartaSearch company hopes to make these validated antibodies more widely available to researchers using broad clinical research technologies," said Todd Chermak, Senior Vice President, Immunology & Proteomics Business Units at CellCarta.
This scalability ensures proteomics solutions meet the needs of both early-stage research and clinical diagnostics, supporting the critical transition from discovery to clinical implementation.
Accelerating Drug Development Through Precision Measurements
The integration aims to enhance the sensitivity and specificity of proteomic analyses, facilitating the development of targeted therapies and personalized medicine approaches. By enabling precise and reproducible protein measurements, the collaboration supports the identification of novel biomarkers, evaluation of therapeutic targets, and monitoring of treatment responses.
The comprehensive proteomics solutions are positioned to accelerate the development of new therapies and improve patient outcomes specifically in immuno-oncologySearch disease, where precise biomarker identification and therapeutic target validation are critical for treatment success.